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SUMMARY 
Background: Gastric antisecretory agents may inhibit 
the synthesis or secretion of gastric mucin during acid 
suppression, which would interfere with mucosal 
protection and limit the efficacy of the agents. 
Methods: Rats were dosed with famotidine, 
omeprazole, or buffer control for 4 weeks. Mucin 
synthesis, mucin histochemistry, mucin carbohydrate 
composition and prostaglandin E, (PGE,) release were 
measured during and after drug treatment. 
Results : PGE, release was maximally inhibited after 2 
weeks of omeprazole or 4 weeks of famotidine. Total 
glycoprotein synthesis was inhibited at all times by 
omeprazole, but only after the cessation of dosing 
with famotidine. Sulphated glycoprotein synthesis was 
inhibited by both drugs at 2 weeks. PGE,release and 
sulphated glycoprotein synthesis were restored to 
control values or more by the 5th day after the end of 
dosing, at which time total glycoprotein synthesis 
was significantly suppressed in both groups. 
Histologically, a reduction of PAS-positive surface 
mucus was observed after 2 weeks of dosing in both 
groups. Both famotidine and omeprazole reduced the 
sialic acid content during and after treatment. 
Conclusions : These results suggest that Iong-term anti- 
secretory therapy also affects the production of factors 
involved in primary gastric mucosal defence, which 
should be considered in the assessment of response to 
treatment in clinical trials. 
IN TR O DUCT I 0  N 
The balance between defensive and aggressive factors in 
the stomach has been proposed as an important com- 
ponent in the aetiology of peptic ulcer disease.' However, 
the mechanisms that regulate the production of acid, 
pepsin and mucosal defence appear to be interrelated, 
and perturbation of one factor may influence another. 
For example, Yamamoto et al. have shown that acid 
suppression by omeprazole and cimetidine is dose- 
dependently accompanied by a reduction of pepsin 
output in the rat stomach.' Takeuchi et al. have reported 
that exogenously added pepsin produced a significant 
increase in frog gastric mucus thickness.3 In addition, it 
has been shown by Ryberg et al. that 1 week of treatment 
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with ranitidine and omeprazole caused a significant 
increase in plasma gastrin levels in the rat ~ t o m a c h . ~  
Pique et aI. have demonstrated a linear correlation 
between increments in acid output and increments in 
mucosal blood flow as they increased the dose of 
pentagastrin in rats5 However, little is known about the 
influence of gastric acid suppression induced by H,- 
receptor antagonists or proton pump inhibitors on the 
defensive factors in the stomach, such as mucin pro- 
duction. We tested the hypothesis that long-term treat- 
ment with these drugs may affect mucin synthesis and 
prostaglandin E, release in the stomach. 
MATERIALS A N D  METHODS 
Reagents 
Famotidine (Pepcid) and omeprazole (Prilosec) were 
obtained from Merck Sharp & Dohme (West Point, PA). 
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Gentamicin was obtained from Flow Laboratories Inc. 
(McLean, VA). DME (Dulbecco's modified Eagle's me- 
dium) F-12 ( 1 : l )  tissue culture medium with L-glu- 
tamine and 1 5 mM HEPES (N-2-hydroxyethylpiperazine- 
N'-2-ethanesulphonic acid), ribonuclease-A, deoxyribo- 
nuclease-I, monosaccharides for standards in the carbo- 
hydrate analysis, and sodium acetate were purchased 
from Sigma Chemical Company (St Louis, MO); tri- 
chloroacetic acid (TCA) and 50% (w/w) glucosamine 
hydrochloride (1.04 TBq/mmol) from Amersham Cor- 
poration (Arlington Heights, IL) : 35S (sulphur-3 5, 
59.2 TBq/mmol) from New England Nuclear Products 
(Boston, MA) ; diethyl ether from Mallinckrodt Inc. (Paris, 
KY): 100% ethyl alcohol from Midwest Grain Products 
Co. (Weston, MO); EcoLite( +) from ICN Biomedicals Inc. 
(Irvine, CA) : trifluoroacetic acid (TFA) from Pierce 
(Rockford, IL) ; caesium chloride (99.99% purity) from 
Schwarz/Mann (Cleveland, OH). The chromatographic 
separations were performed on a Dionex BioLC gradient 
pump module with a model PAD 2 detector, and the 
monosaccharide separation performed on a 4.6 x 
2 50 mm HPIC-AS6 anion-exchange column equipped 
with an AG-6 guard column (Dionex, Sunnyvale, CA). 
Drug administration and dose selection 
Male Wistar rats, weighing 160-180 g, were used in this 
study according to the VA Animal Usage Protocol. 
Famotidine (FAM) at 4mg/kg suspended in 4mM 
NaHCO, (pH S.O), omeprazole (OME) at 30 mg/kg sus- 
pended in 4 miu NaHCO, (pH 8.0), or control buffer, was 
administered by oral gavage to rats once daily. Rats were 
fasted overnight before the experiments but allowed free 
access to water. 
The dose of omeprazole was selected on the basis of the 
reported experience of Yamamoto et al.' Omeprazole 
produces a dose-related decrease in gastric secretory 
volume, acid output, pepsin output, and gastric damage 
in response to stress when administered in doses range 
from 3 to 100mg/kg. A dose of 30mg/kg decreases 
gastric acid output to less than 20% of control values 
without evidence of toxicity, and was selected for use. 
Famotidine was selected as a long-acting H,-antagonist 
that could be administered by gavage once a day. 
Yamamoto et a / .  demonstrated that cimetidine (at a 
maximum dose of 200 mg/kg) decreased the acid output 
to 50% of control levels.' Since the clinically relevant 
dose of cimetidine in humans is at least 50-60 times as 
high as that for famotidine, a dose of 4 mg/kg of 
famotidine was selected for this study. 
Tissue culture 
After 2 or 4 weeks of dosing, and 5 days after the end 
of 4 weeks of dosing, rats were killed by cervical 
dislocation 2-3 h after the last dose. The stomachs were 
immediately excised and the muscular layer was removed 
from the fundus. The mucosal layer was cut into small 
pieces of uniform size and shape ( 2  x 2 mm) using a 
series of blades held in a frame to cut the tissue. The 
pieces were weighed to test for uniformity, and groups of 
10 were found to differ in mass by less than 5%. Ten 
tissue pieces were placed in each plastic culture well 
(diameter 35 mm) with 2 mL of medium consisting of 
DME/F12 (1: 1) L-glutamine, 1 5  mM HEPES, 10% foetal 
bovine serum (FBS) and 0.05 mg/mL gentamicin.6 The 
explants were incubated in the presence of 5 pCi/well D- 
[ 1,6-3H]-glucosamine or 5 pCi/well 35S at 3 7 "C under 
5% C0,/95% air. Wells were also maintained in the 
absence of radioactivity for the measurement of PGE,. 
Measurement of PGE, 
Fifty microlitres of media was collected from each 
unlabelled well before (i.e. immediately after placement 
in culture) and after 3 h incubation, and immediately 
frozen at - 70 "C. PGE, in media was quantified by 
radioimmunoassay (RIA) in the University of Michigan 
Diabetes Centre Ligand Core Lab~ra tory .~  
The PGE, antibody was purchased commercially from 
Cayman Chemical Co. (Ann Arbor, MI). Cross reactivities 
with other prostaglandins are as follows: 1 5-keto-PGE, : 
9.2 %, and PGE, : 5 %, Cross reactivities were less than 
0.2 % for the following prostaglandins: PGA,, PGB,, 
PGB,, PGD,, PGF,,, 6-keto PGF,, PGF,, 13,14-dihydro- 
1 5-keto-PGF2,, and thromboxane B, (manufacturer's 
specifications). PGE, generation was calculated by sub- 
tracting time 0 from the 3-h value to correct for carry- 
over during tissue preparation. 
Assessment of glycoprotein synthesis 
At the end of 6 h of incubation with 'H-glucosamine or 
35S, media and tissue fragments were harvested together. 
After homogenization and sonication, they were centri- 
fuged at 100000 g at 4 "C for 1 h to remove cellular 
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debris. The supernatant was precipitated with 10% TCA 
and 1 % PTA at 4 "C overnight. Then, the samples were 
centrifuged at 500 g for 25 min and the pellets were 
resuspended by sonication. Each pellet was washed 
threefold with 10% TCA/l% PTA and twice with 
ether/ethanoL31 The pellets were dissolved in 2 mL of 
0.6 M KOH and ,H- or 35S-radioactivity was measured by 
liquid scintillation counting.' 
Purijkation of mucin and carbohydrate analysis 
Five rats were dosed in each group at each time point. 
After 4 weeks of dosing, and 5 days after the end of the 
4 weeks' dosing, the fundus was removed and the 
mucosa was homogenized and sonicated in phosphate- 
buffered saline (PBS), pH 7.4, to disrupt cells. The 
resulting suspensions were centrifuged at 38 000 r.p.m. 
(100000 g )  for 1 h at 4 "C. The supernatants were 
applied to a 5 x 100 cm glass column packed with 
Sepharose CL-4B, equilibrated with PBS, and eluted at a 
flow rate of 60 mL/h. The void volume peak, which 
contained the mucin-rich fraction, was pooled, dialysed 
exhaustively against deionized water and lyophilized. 
The samples were digested with protease-free bovine 
deoxyribonuclease (DNase)-I and bovine ribonuclease 
(RNase)-A for 16  h at 37 "C in PBS, pH 7.4, containing 
10 mM MgCl, and 0.02% NaN,; 1 mg of each nuclease 
was added for each 5 mg of mucin. The digest mixture 
was centrifuged at 10000 r.p.m. (15000 g )  for 30 min 
to remove the resulting precipitate, and the supernatant 
was dialysed against PBS at 4 "C. Subsequently, 12.9 g of 
CsCl was added to the dialysed material and the final 
volume adjusted to 24 mL (starting density, 1.38 g/mL). 
The samples (2 x 12  mL tubes) were centrifuged at 
36000 r.p.m. (100000 g )  for 48 h at 4 "C. After the 
gradient had formed, 8 x 1.5-mL fractions were collected 
by aspiration and weighed to determine their specific 
gravity (SG). Fractions 5-7 (SG: 1.35-1.45 g/mL) were 
pooled together, dialysed to remove CsCl and PBS salts, 
and lyophilized. The sample was hydrolysed and applied 
to a high performance liquid chromatography ion ex- 
change column with pulsed amperometric detection 
(Dionex) for carbohydrate analysis as described pre- 
vious." 
Histological evaluation 
After 2 or 4 weeks of dosing, and 5 days after the end 
of 4 weeks of dosing, the stomachs were excised and 
the oxyntic mucosa was cut into 2 mm wide tissue strips 
and preserved in neutral, buffered 4 % formaldehyde 
solution. After dehydration, the specimens were em- 
bedded in paraffin, sectioned at  5 PM, and stained with 
haematoxylin-eosin or PAS-Alcian blue.1° 
Statistical analysis 
The results are expressed as means + s.e. N is the number 
of rats used in each experiment. Statistical analysis was 
carried out using Student's t-test. P-values of less than 
0.05 were considered to be significant. 
RESULTS 
Prostaglandin E ,  release 
The results of each assay are expressed as a percentage of 
control wells at each time point. As shown in Figure 1, 
PGE, release was initially inhibited after 2 weeks of OME 
( 4 3 f 4 % ,  P < 0.001) and 4 weeks of FAM (69*8%, P 
< 0.01), but recovered to a level greater than measured 
in control wells by the 5th day after the end of dosing 
in both groups. 
Glycoprotein synthesis 
The results of each assay are expressed as a percentage of 
control wells at each time point. Total glycoprotein 
synthesis, which is expressed as 'H-glucosamine in- 
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Figure 1. PGE, release after 2 or 4 weeks dosing with 
4 mg/kg FAM and 30 mg/kg OME, and 5 days after the end of 4 
weeks of dosing, measured by radioimmunoassay (RIA). The 
values are expressed as a percentage of control wells at each 
time point. ( n  = 5 :  *P < 0.05. **P < 0.01, ***P < 0.001, 
compared with control.) 
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- omeprazole 
I" 
2 weeks 4 weeks 5 days after 
Figure 4. Characteristic vacuolar degeneration of parietal cells 
(arrowheads) is observed after 2 weeks of dosing with 
30 mg/kg OME, stained with haematoxylin-eosin. ( x 400) 
Figure 2 .  "H-glucosamine incorporation into fundic tissues and 
new glycoprotein synthesis after 2 or 4 weeks of dosing with 
4 mg/kg FAM and 30 mg/kg OME, and 5 days after the end of 4 
weeks of dosing, measured by glycoprotein precipitation using 
100/,TCA/I%PTA and lipid extraction. The values are expressed 
as a percentage of control wells at each time point. ( n  = 5: *P < 
0.05, ***P < 0.001, compared with control.) 
to control values or more by the 5th day after the end of 
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Figure 3 .  "S incorporation into fundic tissues and new 
glycoprotein synthesis after 2 or 4 weeks of dosing with 
4 mg/kg PAM and 30 mg/kg OME, and 5 days after the end of 4 
weeks of dosing, measured by glycoprotein precipitation using 
l0XTCA/1 YIPTA and lipid extraction. The values are expressed 
as a percentage of control wells at each time point. (n = 5: 
*I' < 0.05) 
corporation, is shown in Figure 2.  Total glycoprotein 
synthesis was significantly suppressed at all time points 
by OME (84 i 1 % to 9 4 i  1 %), but suppression was 
observed only after the cessation of dosing with FAM 
(84 i 2 %). As shown in Figure 3, sulphated glycoprotein 
synthesis was initially significantly inhibited after 2 
weeks of dosing in both groups (83  & 7% for OME, 
8 5 i 6 % for FAM-treated group) but synthesis recovered 
Histological evaluation 
Vacuolation of parietal cells was observed at all time 
points in both dosed groups, however, most remarkably 
present after 2 weeks of dosing with OME as shown in 
Figure 4. As shown in Figure 5, PAS-positive surface 
mucus production was reduced after 2 weeks of dosing 
with OME and FAM. The reduction was not observed at 
other time points in either treated group. 
Carbohydrate composition 
The carbohydrate composition data are expressed as a 
percentage of total carbohydrate content for each mono- 
saccharide. Whereas there were only minor changes in 
the relative compositions of the neutral sugars, sialic acid 
content fell dramatically during and after dosing with 
OME and FAM (Table 1). 
DISCUSSION 
H,-receptor antagonists and proton pump inhibitors are 
widely used for gastric acid suppression, and the elim- 
ination of acid is considered the most effective therapy for 
peptic ulcer diseases. However, it is also known that the 
recurrence rate of ulcers is rather high after initial 
healing with those drugs.ll In addition, little has been 
known about the effect of long-term treatment with these 
drugs on the defensive factors in the stomach, such as 
mucin production. In this study, therefore, we tested the 
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Figure 5 .  PAS-positive surface mucus production is remarkably 
reduced after 2 weeks dosing with 4 mg/kg FAM and 
30 mg/kg OME: stained with PAS-alcian blue. (a) control, (b) 
FAM- and (c) OME-dosed fundic mucosa. ( x 400) 
hypothesis that long-term treatment with omeprazole 
and famotidine may affect mucin production and PGE, 
release in the stomach, and found that changes in PGE, 
and glycoproteins were produced by these agents. 
Baker et al. have demonstrated that there are significant 
correlations between the output of gastric acid and 
gastric outputs of PGE and PGF in response to in- 
travenous infusions of pentagastrin, histamine and in- 
Table 1. Carbohydrate composition of fundic mucin during and 
after dosing with FAM and OME 
Group Fuc GalNAc GlcNAc Gal SA 
Controls 17.15 12.13 37.06 32.41 1.25 
PAM (4 weeks) 17.50 6.00 41.33 34.87 0.30 
FAM (5 days after) 21.43 6.16 38.44 33.85 0.12 
OME (4 weeks) 21.17 9.57 37.58 31.64 0.04 
OME (5 days after) 19.09 11.63 35.52 33.46 0.30 
Carbohydrate composition of fundic mucin after 4 weeks 
treatment with 4 mg/kg FAM and 30 mg/kg OME, and 5 days 
after the end of the 4 weeks of dosing. 
The results are expressed as a percentage of total carbohydrate 
content for each monosaccharide. 
Abbreviations : Fuc : fucose : GalNAc : N-acetylgalactosamine: 
GlcNAc : N-acetylglucosamine : Gal : galactose: SA: sialic acid 
sulin in cat gastric juice, and have also shown that a 
significant correlation is observed between pepsin output 
and endogenous PGE and PGF secretion.12 Yamamoto et 
al. have reported that acid suppression by omeprazole 
and cimetidine is dose-dependently accompanied with 
reduction of pepsin output in the rat stomach., The 
present work shows that PGE, release was suppressed 
during drug dosing, and recovered to a level more 
than that in control wells by the 5th day after the 
end of dosing in both groups. This suggests that acid 
suppression results in a coordinated reduction in prosta- 
glandin synthesizing capacity in the mucosa, but that 
this function quickly adapts to normal levels or higher 
promptly after the discontinuation of therapy. There- 
fore, post-dose effects in the gastric mucosa cannot be 
attributed to impaired prostaglandin release. Preliminary 
work from our laboratory has shown that PGE, release 
stimulated by histamine was significantly suppressed by 
the H,-receptor antagonist cimetidine in both fundic and 
antral explants in the rabbit.13 This suggests that the 
blockade of histamine H,-receptor itself, in addition to the 
suppression of acid and pepsin output, may have con- 
tributed to the maximum decrease of PGE, secretion after 
4 weeks in FAM-dosed group. 
Ryberg et al. have demonstrated that gastric acid 
suppression for 28 days with ranitidine and omeprazole 
caused a significant increase in plasma gastrin con- 
centration, and a consequent increase in the density of 
enterochromaffin-like (ECL) cells, histamine concen- 
tration and the histamine-producing enzyme, histidine 
decarboxylase (HDC) activity in the rat oxyntic mucosa.14 
In the present study, the hypergastrinaemia and the 
histamine released from ECL cells may have restored the 
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output of acid and pepsin to some extent, caused a 
gradual increase in total glycoprotein synthesis (i.e. 3H- 
glucosamine incorporation) and sulphated glycoprotein 
synthesis during treatment in both groups. In fact, 
histological evaluation has shown that the vacuolar 
degeneration of parietal cells ((Figure 4), which is 
considered to reflect dilation of the secretory canaliculi15) 
is less remarkable after 4 weeks than 2 weeks in OME- 
treated group. The histological examination also showed 
that the volume of PAS-positive surface mucus after the 
4-week treatments was similar to that seen in control 
tissues, whereas it was significantly reduced after only 2 
weeks in both dosed groups (Figure 5). 
In this study, glycoprotein sulphation was restored to 
control values or greater by the 5th day after the end 
of treatment, while "H-glucosamine incorporation was 
still suppressed in both groups. The proteolytic action of 
pepsin on gastric mucus is well known.16 Mikuni- 
Takagaki & Hotta have shown that sulphated glyco- 
proteins of gastric mucosa may inhibit peptic activity by 
binding the enzyme, but that non-sulphated glyco- 
proteins do not exhibit the apparent pepsin binding and 
inhibitory activity (although they have a similar mono- 
saccharide and amino acid composition to sulphated 
glycoproteins).17 Moreover, they have reported that 
sulphated glycoproteins are intrinsically resistant to 
peptic digestion. Kim et al. have demonstrated that 
amylopectin sulphate, a synthetic sulphated polysac- 
charide, tends to bind to gastric mucin under conditions 
of low pH, and that the binding is reversible." This may 
have led to the apparent discrepancy between "H- and 
'j5S- incorporation when the mucin was recovered in the 
presence of pepsin and acid 5 days after the end of drug 
exposure. Histologically, PAS-positive surface mucus 
production was not reduced at this time point in either 
of the treated groups. 
There is a very small quantity of sialic acid in gastric 
mucus glycoprotein, which is one of five different 
monosaccharides constituting the carbohydrate side 
chains. However, sialic acid may play an important role 
in the defence of the stomach. It has been demonstrated 
by Slomiany et al. that the removal of peripheral fucose or 
N-acetylgalactosamine caused, in each case, only about 
a 5 % reduction in glycoprotein viscosity, while an 18 % 
drop in the viscosity occurred following the removal of 
sialic acid.19 They also reported that removal of fucose or 
peripheral N- acetylgalactosamine increased the hydro- 
gen ion retardation capacity of mucin by 7%, while a 
28% increase was seen following the removal of sialic 
acid. Our present study shows that sialic acid content fell 
dramatically during and after dosing with omeprazole 
and famotidine, whereas there were only minor changes 
in the relative compositions of the neutral sugars. This 
result is similar to the findings of Vianello et aL20 on 
gastric mucus after 6 weeks treatment with farnotidine in 
duodenal ulcer patients. Furthermore, there is a clear 
association between hypochlorhydria and gastrointes- 
tinal infections.21 Therefore, it may be suggested that 
terminal sialic acid residues on some sugar chains of the 
mucus glycoprotein are lost by the action of bacterial 
neuraminidases that may be elaborated in the gastric 
mucus under conditions of long-term suppression of 
acid.22 Ohara et al. have shown that a single admin- 
istration of high dose (200 pmollkg) omeprazole caused 
a significant decrease (to 182% of control) of mucus 
glycoprotein, but did not change carbohydrate com- 
position in the rat Thus, long-term anti- 
secretory therapy may have important influences on 
factors involved in gastric mucosal defence, and these 
should be considered in clinical trials that assess patients' 
response to drug treatment. 
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